LSL Pharma Group Inc. develops and commercializes sterile pharmaceutical, cosmetic, and natural health products. The company faces significant concerns, including a low gross margin of 11.9% and a negative net margin of -15.3%, indicating profitability challenges. While the current ratio of 1.16 suggests adequate liquidity, the quick ratio of 0.44 raises concerns about immediate financial health. Additionally, a high debt-to-equity ratio of 2.21 may pose risks in a rising interest rate environment. Overall, LSL's financial metrics reflect a struggling business model that requires improvement.
Loading financial metrics...
Company has $967K in cash but burned $1.5M last quarter. At this burn rate, only 0.7 quarters of runway remain without additional financing.
Gross profit margin declined from 29.4% to 8.3% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-7.3M over the last year, representing 17.5% of revenue.
Debt of $48.6M is 50.2x the company's cash position of $967K.
Exceptional revenue growth of 80.0% YoY demonstrates strong market demand and competitive positioning.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)